HC Wainwright Reaffirms “Neutral” Rating for Lisata Therapeutics (NASDAQ:LSTA)

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Tuesday, April 21st. cut shares of Lisata Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $15.00.

Lisata Therapeutics Stock Performance

NASDAQ:LSTA traded up $0.11 during trading hours on Friday, reaching $3.19. The company’s stock had a trading volume of 7,380 shares, compared to its average volume of 139,696. The firm has a market capitalization of $29.02 million, a price-to-earnings ratio of -1.71 and a beta of 0.81. The firm has a 50-day simple moving average of $4.25 and a 200-day simple moving average of $3.36. Lisata Therapeutics has a 1 year low of $1.81 and a 1 year high of $5.07.

Lisata Therapeutics (NASDAQ:LSTA) last issued its earnings results on Monday, May 11th. The company reported ($0.50) EPS for the quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cerity Partners LLC bought a new position in shares of Lisata Therapeutics in the second quarter worth approximately $32,000. CIBC Bancorp USA Inc. bought a new position in shares of Lisata Therapeutics in the third quarter worth approximately $37,000. SOL Capital Management CO bought a new position in shares of Lisata Therapeutics in the first quarter worth approximately $61,000. Ground Swell Capital LLC purchased a new position in shares of Lisata Therapeutics during the third quarter valued at approximately $62,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Lisata Therapeutics by 6.1% during the fourth quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock valued at $230,000 after purchasing an additional 7,093 shares during the last quarter. Institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.